ClearPoint Neuro (CLPT) Asset Writedowns and Impairment (2020 - 2026)
ClearPoint Neuro recorded quarterly Asset Writedowns and Impairment of -$95000.0 in Q1 2026, up 51.53% quarter-over-quarter from -$196000.0 in Q4 2025, and down 143.78% year-over-year from $217000.0 in Q1 2025.
ClearPoint Neuro's Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at -$95000.0 for Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment fell 143.78% year-over-year to -$95000.0; the TTM figure through Mar 2026 stood at -$291000.0 (down 534.33% YoY), while the FY2025 annual figure was $21000.0, up 107.09% from the prior year.
- Asset Writedowns and Impairment came in at -$95000.0 for Q1 2026 at ClearPoint Neuro, up from -$196000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $449000.0 in Q3 2023 to a low of -$361000.0 in Q2 2024.
- A 5-year average of $55071.4 and a median of $13000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- Across the five-year window, Asset Writedowns and Impairment tumbled 2133.33% in 2022 and soared 1520.0% in 2023, its largest moves.
- ClearPoint Neuro's Asset Writedowns and Impairment stood at -$25000.0 in 2022, then jumped by 1520.0% to $355000.0 in 2023, then tumbled by 40.56% to $211000.0 in 2024, then tumbled by 192.89% to -$196000.0 in 2025, then surged by 51.53% to -$95000.0 in 2026.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$95000.0, -$196000.0, and $217000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | ClearPoint Neuro | 375.84 Mn | 340.24 Mn | 7.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95,000.00 |
| Mar 31, 2026 | -95,000.00 |
| Dec 31, 2025 | -196,000.00 |
| Dec 31, 2025 | -196,000.00 |
| Mar 31, 2025 | 217,000.00 |
| Mar 31, 2025 | 217,000.00 |
| Dec 31, 2024 | 211,000.00 |
| Dec 31, 2024 | 211,000.00 |
| Jun 30, 2024 | -361,000.00 |
| Jun 30, 2024 | -361,000.00 |
| Mar 31, 2024 | -146,000.00 |
| Mar 31, 2024 | -146,000.00 |
| Dec 31, 2023 | 355,000.00 |
| Dec 31, 2023 | 355,000.00 |
| Sep 30, 2023 | 449,000.00 |
| Sep 30, 2023 | 449,000.00 |
| Jun 30, 2023 | 283,000.00 |
| Jun 30, 2023 | 283,000.00 |
| Mar 31, 2023 | 171,000.00 |
| Mar 31, 2023 | 171,000.00 |
| Dec 31, 2022 | -25,000.00 |
| Dec 31, 2022 | -25,000.00 |
| Sep 30, 2022 | -82,000.00 |
| Sep 30, 2022 | -82,000.00 |
| Jun 30, 2022 | 51,000.00 |
| Jun 30, 2022 | 51,000.00 |
| Mar 31, 2022 | -61,000.00 |
| Mar 31, 2022 | -61,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Sep 30, 2021 | 78,000.00 |
| Sep 30, 2021 | 78,000.00 |
| Jun 30, 2021 | 89,000.00 |
| Jun 30, 2021 | 89,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Dec 31, 2020 | 14,000.00 |
| Dec 31, 2020 | 14,000.00 |
| Sep 30, 2020 | 11,000.00 |
| Sep 30, 2020 | 11,000.00 |